{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:01:59Z","timestamp":1783551719709,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.autrev.2011.05.017","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T13:19:49Z","timestamp":1307107189000},"page":"226-230","source":"Crossref","is-referenced-by-count":60,"title":["Autoimmune blistering diseases of the skin"],"prefix":"10.1016","volume":"11","author":[{"given":"Michael","family":"Sticherling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Erfurt-Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2011.05.017_bb0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1749-6632.2009.04737.x","article-title":"Autoimmune bullous dermatoses: a review","volume":"1173","author":"Patricio","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2011.05.017_bb0010","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clim.2009.11.006","article-title":"Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3","volume":"134","author":"Nagel","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0020","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.4049\/jimmunol.178.9.5982","article-title":"Dissecting the anti-desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients","volume":"178","author":"Qian","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0025","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1600-0625.2009.00934.x","article-title":"Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis","volume":"18","author":"Grando","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2006.12.067","article-title":"The specific proteolysis hypothesis of pemphigus: does the song remain the same","volume":"70","author":"Cirillo","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.autrev.2011.05.017_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4049\/jimmunol.182.1.711","article-title":"Involvement of the apoptotic mechanism in pemphigus foliaceus autoimmune injury of the skin","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.jid.5701248","article-title":"Outside-in signaling through integrins and cadherins: a central mechanism to control epidermal growth and differentiation?","volume":"128","author":"Muller","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0045","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI28547","article-title":"T cell control in autoimmune bullous skin disorders","volume":"116","author":"Hertl","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.05.017_bb0050","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJM199012203232503","article-title":"Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia","volume":"323","author":"Anhalt","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.05.017_bb0055","doi-asserted-by":"crossref","first-page":"e12250","DOI":"10.1371\/journal.pone.0012250","article-title":"The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human","volume":"5","author":"Schepens","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2011.05.017_bb0060","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","volume":"1","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2011.05.017_bb0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/157016309789869065","article-title":"Current treatment of autoimmune blistering diseases","volume":"6","author":"Kasperkiewicz","year":"2009","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0070","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2011.05.017_bb0075","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2011.05.017_bb0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmue blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0085","first-page":"1","article-title":"Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the Initial use to 2007","volume":"5","author":"Peterson","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.autrev.2011.05.017_bb0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0095","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","article-title":"Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases","volume":"5","author":"Zillikens","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2011.05.017_bb0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/08923970902814145","article-title":"Pemphigus: the promises of peptide immunotherapy","volume":"31","author":"Di Bisceglie","year":"2009","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2011.05.017_bb0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318600-000000000-00000","article-title":"Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management","volume":"27","author":"Mutasim","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.autrev.2011.05.017_bb0125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1610-0387.2008.06974.x","article-title":"Research in practice: diagnosis of subepidermal autoimmune bullous disorders","volume":"7","author":"Schmidt","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2011.05.017_bb0130","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1365-4632.2006.02861.x","article-title":"Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship?","volume":"45","author":"Wilczek","year":"2006","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2011.05.017_bb0135","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1582-4934.2007.00081.x","article-title":"IgG4 autoantibodies induce dermal-epidermal separation","volume":"11","author":"Mihai","year":"2007","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.autrev.2011.05.017_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","article-title":"Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid","volume":"144","author":"Iwata","year":"2008","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2011.05.017_bb0145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2133.2008.08858.x","article-title":"IgE autoantibodies against the intracellular domain of BP180","volume":"160","author":"Dresow","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0150","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.05.017_bb0160","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2353\/ajpath.2010.090744","article-title":"Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen","volume":"176","author":"Wang","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0165","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.4049\/jimmunol.0901412","article-title":"T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita","volume":"184","author":"Sitaru","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0170","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-4632.2007.03214.x","article-title":"Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience","volume":"46","author":"Alonso-Llamazares","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0175","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.autrev.2008.05.006","article-title":"Celiac disease: from gluten to autoimmunity","volume":"7","author":"Briani","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.05.017_bb0180","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/jmg.2007.053991","article-title":"Myosin IXB gene region and gluten intolerance: linkage to coeliac disease and a putative dermatitis herpetiformis association","volume":"45","author":"Koskinen","year":"2008","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.autrev.2011.05.017_bb0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2133.2008.08629.x","article-title":"Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis","volume":"159","author":"Hull","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2011.05.017_bb0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1468-3083.2009.03188.x","article-title":"Guidelines for the diagnosis and treatment of dermatitis herpetiformis","volume":"23","author":"Caproni","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.autrev.2011.05.017_bb0195","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1365-2036.2008.03660.x","article-title":"No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study","volume":"27","author":"Lewis","year":"2008","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T05:55:59Z","timestamp":1543730159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1568997211001194"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.05.017","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}